Poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, a class of targeted anticancer therapies, prevent genetic ...
New findings could help identify patients likely to become resistant to anti-cancer drugs and aid exploring different ways to ...
Dr. Chandler Park sat down for an interview with CURE® to discuss the biggest takeaway from the 2025 ASCO GU Symposium in ...
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...
LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with ...
BRCA1 and BRCA2 genes play a crucial role in repairing damaged DNA. Mutations in BRCA1 and BRCA2 substantially increase the likelihood of breast and ovarian cancer, respectively. This new research ...
Therapeutics announced plans for a Phase 2 trial evaluating the combination of stenoparib with temozolomide, a DNA-alkylating ...
Pfizer Ltd has announced that the Scottish Medicines Consortium (SMC) has accepted Talzenna (talazoparib) in combination with ...
LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with PARP inhibitor in HRD (homologous recombination deficiency) cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback